AKRIKHIN produces effective, affordable and high quality medicines in the most popular therapeutic areas in Russia
The company is in the top 5 leading local pharmaceutical producers by sales on the Russian market showing the significant growth and development rates.
The company’s portfolio includes about 200 products, more than 100 of them are produced at the manufacturing facility in Moscow region.
Our drugs are related to the most essential pharmacotherapeutic groups – tuberculosis, diabetes, dermatology, cardiology, neurology, gynecology, etc. and produced in total compliance with the GMP standards. 45% of products in company’s sales volume are included in the Essential Drugs List.
Akrikhin is one of few Russian producers to have its own Research and Development (R&D) Center. This is a research, analysis and technological center with the very latest technical equipment and analytical instruments. The center’s main focus is generics. Taking into consideration the highly competitive generics market, Akrikhin is concentrated on developing advanced generics and also new forms of known combinations (so called “generic plus” versions). During 2014-2015 within the framework of the import substitution program the company has brought 10 products to the market.
Akrikhin manufacturing facility is a modern complex located on 36 hectares land plot, 20 km from Moscow. The facility comprises of two workshops producing finished pharmaceutical products: solid & semi-solid finished dosage forms. Production volumes are more than 80 mln packs per year. In 2011-2017 the company has realized a largescale investment program of modernization of manufacturing facility with total investments about 50 mln $.
About 1500 people work at Akrikhin, more that 800 of them are based at the manufacturing facility and 500 present company’s field force in 63 regions of Russia.
News from AKRIKHIN
France and Greece are introducing mandatory vaccination against COVID-19 for doctors. In Russia, vaccination is mandatory for 60% of employees of institutions and enterprises of certain groups, including healthcare sector. […]
The post Doctors do not have enough information about the side effects of vaccines appeared first on GxP News.
The amount of the one-off payment for citizens who have complications after vaccination may be increased, according to RBC. At the moment, this payment is 10,000 rubles, having not been […]
The post The Ministry of Health proposes to increase compensation for complications from vaccination appeared first on GxP News.
The Working Group on the implementation of the regulatory guillotine in the healthcare sector considered the ways to improve the rules for the supply of medicines. The Russian Ministry of […]
The post The Ministry of Health will create a roadmap for improving the drug supply system appeared first on GxP News.
Scientists of the Immanuel Kant Baltic Federal University (BFU) have developed a method that increases the efficiency of cardiovascular diseases treatment and also provides an opportunity to determine the patient’s […]
The post Russia creates a system for evaluating the effectiveness of cardiac medications appeared first on GxP News.